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Identity 
Other names: IL-23, IL-23A, IL23P19, MGC79388, 
P19, SGRF 








The transcript is 1041 bp, with a 166 bp 5' untranslated 






The IL23A protein (IL-23p19 subunit) is covalently 
linked to a p40 subunit (IL12B, IL-12p40), which is 
shared with IL-12, to form IL-23 (Oppmann et al., 
2000). The IL23A protein requires IL12B for secretion. 
The receptor for IL-23 is formed by the association of a 
specific IL-23 receptor (IL23R) and IL-12Rbeta1 
(IL12RB1), which is shared with the receptor for IL-12 
(Parham et al., 2002). The receptor for IL-23 is 
constitutively associated with Jak2 (Janus kinase 2) and 
predominantly activates Stat3, with less Stat4 
activation than IL-12. 
Description 
The protein consists of 189 amino acids and is 20.7kD, 
comprising a 19 amino acid signal peptide and a mature 
peptide (170 amino acids, 18.7 kD). 
 
IL23A gene. The IL23A gene spans a region of 1531 bp composed of 4 exons [untranslated region (UTR), light blue; coding region, dark 
blue] with 328 bp, 99 bp, 147 bp and 467 bp in length, and 3 introns (brown) with 219 bp, 166 bp and 105 bp in length. 
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IL23A protein. The IL23A protein is composed of a signal 
peptide (light green) and a mature peptide (dark green) with 
four alpha-helices (dark yellow). 
Expression 
IL-23 is secreted by dendritic cells (DCs) and 
phagocytic cells activated with pathogens and 
pathogen-associated molecular patterns that act throug  
toll-like receptors (TLRs) (Hunter, 2005; Kastelein et 
al., 2007; Goriely et al., 2008). The TLR2 ligand 
peptidoglycan, a cell wall component of Gram-positive 
bacteria, preferentially promotes the expression of 
IL23A but not IL12A through activation of a cytosolic 
receptor, nucleotide-binding oligomerization domain 2 
(NOD2), with TLR2. Activation of the C-type lectins-
Syc-CARD9 signaling pathway by the beta-glucan 
curdlan also induces IL-23 production by DCs 
(LeibundGut-Landmann et al., 2007). Prostaglandin E2 
(PGE2) and ATP act on their G-protein-coupled 
receptors, EP2 and EP4 (PGE2) and P2Y (ATP), to 
enhance IL-23 production via an increase in cAMP 
concentration (Sheibanie et al., 2004; Yao et al., 2009; 
Schnurr et al., 2005). Lactic acid also facilitates IL-23 
production (Shime et al., 2008). Although these factors 
themselves do not induce IL-23 production, they can
shift the balance between IL-12 and IL-23 secretion by 
activated DCs or macrophages toward IL-23. Polarized 
Th1 and Th2 cells highly express IL23A mRNA but 
not IL12B mRNA (Oppmann et al., 2000). The roles of 
IL23A mRNA expression in T cells are unknown. 
Function 
IL-23 receptor is mainly expressed on 
activated/memory T cells and natural killer (NK) cells. 
Monocytes, macrophage and DCs also express IL-23 
receptor at low levels (Parham et al., 2002). Although 
IL-23 does not directly stimulate the initial 
differentiation of naive T cells to Th17 cells, it is
essential for the full differentiation of Th17 cells and 
promotes their expansion and maintenance to induce 
IL-17A production (Korn et al., 2009). NKT cells 
(Rachitskaya et al., 2008) and innate lymphoid cells 
such as lymphoid tissue induce (LTi)-like cells 
(Takatori et al., 2009; Buonocore et al., 2010) expr ss 
IL-23 receptor and retinoic-acid-related orphan 
receptor (ROR) gammat and produce IL-17 in response 
to IL-23. IL-1beta and IL-23 also costimulate 
gammadelta T cells to induce IL-17 production without 
T cell receptor engagement (Sutton et al., 2009). 
Homology 
IL23A has homology with four-helix bundle cytokine 
family members such as IL12A (IL-12p35), IL-6, and 
G-CSF. IL23A and IL12A have the highest homology, 





Promotion of tumor incidence and growth 
The expression of IL-23A mRNA is significantly 
elevated in various human cancers, such as melanoma, 
colon, ovarian, head and neck, lung, breast, and 
stomach cancers, when compared with adjacent normal 
tissues (Langowski et al., 2006). IL-23 upregulation s 
also observed in sera from multiple myeloma patients 
(Prabhala et al., 2010). A deficiency of IL23A 
promotes increased infiltration of cytotoxic T cells into 
the transformed tissue and mediates resistance to 
chemically induced tumors. IL-23 facilitates the 
induction of inflammation and angiogenesis in the 
tumor microenvironment and inhibits CD8+ T cells 
infiltration, thereby promoting tumor incidence and 
growth (Langowski et al., 2006; Langowski et al., 
2007; Martin-Orozco and Dong, 2009). It has been 
suggested that IL-23 also suppresses carcinogenesis 
and metastasis in mouse models, where it acts 
independently of IL-17A (Teng et al., 2010). Stat3 
signaling shifts the balance between IL-23 and IL-12 
toward IL-23 in the tumor microenvironment 
(Kortylewski et al., 2009). In tumor-associated 
regulatory T cells, IL-23-activated Stat3 induces the 
upregulation of Foxp3 and IL-10.  
Anti-tumor effects 
In several mouse tumor models, IL-23 overexpression 
in tumors (Overwijk et al., 2006) or intratumoral 
injection of IL-23-introduced DCs (Hu et al., 2006) has 
been shown to induce tumoral infiltration of CD8+ T 
cells and to inhibit tumor growth. Systemic 
administration of IL-23 also suppresses the growth of a
pre-existing tumor in mice (Kaiga et al., 2007). 
Ovarian cancer 
Note 
The occurrence of specific single nucleotide 
polymorphisms (SNPs) in the IL23R gene is increased 
in ovarian cancer patients compared with controls 
(dbSNPs: rs10889677) and in advanced ovarian cancer 
stage (dbSNPs: rs11465817) (Zhang et al., 2010). 
Inflammation and inflammatory 
diseases 
Note 
IL23A and IL23R knockout mice are resistant to the 
development of experimental autoimmune  
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encephalomyelitis and collagen-induced arthritis 
(Hunter, 2005; Kastelein et al., 2007; Abraham and 
Cho, 2009; Korn et al., 2009). IL-23A deficiency or
treatment with anti-IL-23A blocking antibodies 
suppresses intestinal inflammation induced in IL-10-
deficient mice. Ubiquitous overexpression of IL-23A in 
mice results in multi-organ inflammation. Therefore, 
IL-23 upregulation is thought to promote many 
inflammatory and autoimmune diseases. Many SNPs in 
the IL23R gene are reported to be significantly 
associated with Crohn's disease, ulcerative colitis, 
psoriasis, and ankylosing spondylitis. In particular, n 
uncommon allele at Arg381Gln (dbSNP: rs11209026) 
in the IL23R gene is associated with protection from 
Crohn's diseases, ulcerative colitis, and psoriasis. 
T-cell-independent colitis 
Note 
IL-23 is involved in bacteria-driven innate immune 
colitis in Rag-/- mice. Recently, Buonocore et al. 
reported that IL-23 induces IL-17 and IFN-gamma 
expression by innate lymphoid cells expressing Thy-1, 
Stem cell antigen 1 (Sca-1), RORgammat and IL23R to 
mediate acute and chronic innate immune colitis 
(Buonocore et al., 2010). 
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